Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Histogenics
Waltham, Massachusetts, United Stateshistogenics.com ↗
- Ownership
- Private
- Employees
- ~39
- Development stage
- Other
01
Overview
Histogenics’ lead product candidate NeoCart was an autologous neocartilage tissue implant designed to regenerate cartilage using a patient’s own cells. It reached Phase 3 clinical trials in the US under a Special Protocol Assessment. Published data showed durable responses sustained for four years or more. Another product candidate, VeriCart™, was being developed as a single-step collagen scaffold for small cartilage defects.
- Therapeutic areas
- OtherRheumatology
- Modalities
- Cell therapyTissue engineeringScaffold-based therapy
- Industry
- Implantable Medical Devices
02
Partnerships
Sofinnova VenturesSplit Rock PartnersBioMed VenturesFinTech GIMV Fund L.P.Altima PartnersFoundation Medical PartnersInflection Point CapitalBoston Millennia Partners
Beyond the preview
Go deeper on Histogenics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Histogenics.